Welcome to CDC Stacks | Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 - 41548 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015
Filetype[PDF - 466.77 KB]


Details:
  • Personal Authors:
  • Keywords:
  • Pubmed ID:
    27410239
  • Pubmed Central ID:
    PMC4943633
  • Description:
    Background

    In 1980, human diploid cell vaccine (HDCV, Imovax Rabies, Sanofi Pasteur), was licensed for use in the United States.

    Objective

    To assess adverse events (AEs) after HDCV reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system.

    Methods

    We searched VAERS for US reports after HDCV among persons vaccinated from January 1, 1990–July 31, 2015. Medical records were requested for reports classified as serious (death, hospitalization, prolonged hospitalization, disability, life-threatening-illness), and those suggesting anaphylaxis and Guillain-Barré syndrome (GBS). Physicians reviewed available information and assigned a primary clinical category to each report using MedDRA system organ classes. Empirical Bayesian (EB) data mining was used to identify disproportional AE reporting after HDCV.

    Results

    VAERS received 1,611 reports after HDCV; 93 (5.8%) were serious. Among all reports, the three most common AEs included pyrexia (18.2%), headache (17.9%), and nausea (16.5%). Among serious reports, four deaths appeared to be unrelated to vaccination.

    Conclusions

    This 25-year review of VAERS did not identify new or unexpected AEs after HDCV. The vast majority of AEs were non-serious. Injection site reactions, hypersensitivity reactions, and non-specific constitutional symptoms were most frequently reported, similar to findings in pre-licensure studies.

  • Document Type:
    Journal Article
  • Collection(s):
    CDC Public Access
No Related Documents.
You May Also Like:
  1. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
    Personal Author:
    Shimabukuro, Tom T.; Nguyen, Michael; Martin, David; DeStefano, Frank;
    Published:
    Jul 22 2015
    Source:
    Vaccine. 33(36):4398-4405.
    Description:
    The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) conduct post-licensure vaccine safety monitoring using the Vaccine Adverse Event Reporting System (VAERS), a spontaneous (or passive) reporting syste...
    File Type:
    Filetype[PDF - 580.38 KB]
  2. Surveillance for safety after immunization; vaccine adverse event reporting system (VAERS) - United States 1991-2001
    Personal Author:
    Ball, Robert; Braun, M. Miles; Chen, Robert T.; Ellenberg , Susan S.; English-Bullard, Roseanne; Haber, Penina; Iskander, John K.; Mootrey, Gina T.; Pless, Robert P.; Pool, Vitali; Wise, Robert P.; Zhou, Weigong;
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    January 24, 2003
    Series:
    MWWR. Surveillance summaries : Morbidity and mortality weekly report. Surveillance summaries ; 52, no. 1
    Description:
    PROBLEM/CONDITION: Vaccines are usually administered to healthy persons who have substantial expectations for the safety of the vaccines. Adverse events after vaccinations occur but are generally rare. Some adverse events are unlikely to be detected ...
    File Type:
    Filetype[PDF - 272.27 KB]
  3. Understanding the Vaccine Adverse Event Reporting System (VAERS)
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.); United States. Food and Drug Administration.; American Academy of Family Physicians.; American Academy of Pediatrics.;
    Published:
    February 2013
    Description:
    • The Vaccine Adverse Event Reporting System (VAERS) is one component of the United States’ comprehensive vaccine safety monitoring system. : • VAERS reports are monitored carefully by the Centers for Disease Control and Prevention (CDC) and th...
    File Type:
    Filetype[PDF - 295.10 KB]
  4. VAERS : Vaccine Adverse Event Reporting System : a national program for monitoring vaccine safety
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.); United States. Food and Drug Administration.;
    Published:
    12/17/03
    Description:
    The Vaccine Adverse Event Reporting System (VAERS) is a national program that monitors the safety of vaccines after they are licensed. VAERS is managed by the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administra...
    File Type:
    Filetype[PDF - 466.12 KB]
  5. VAERS : Vaccine Adverse Event Reporting System : a national program for monitoring vaccine safety
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.); United States. Food and Drug Administration.;
    Published:
    8/30/16
    Description:
    The Vaccine Adverse Event Reporting System (VAERS), is a national program managed by the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) to monitor the safety of all vaccines licensed in the Unite...
    File Type:
    Filetype[PDF - 375.51 KB]